SCHEMBL1104983

SCHEMBL1104983

Oc1ccc(Cl)cc1C1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 1/20 0.51
SLC6A2 P23975 3/20 0.48
SLC6A4 P31645 3/20 0.48
SLC6A3 Q01959 2/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
HTR1A P08908 2/20 0.46
HTR3A P46098 1/20 0.44
KCNH2 Q12809 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HTR2C P28335 3/20 0.43
HTR2B P41595 1/20 0.43
MAPK1 P28482 1/20 0.42
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTR6 P50406 2/20 0.40
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1095262 0.98 QDPR (0.50) QDPRSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL12611071 0.87 HSD17B10 (0.48) KMT2AMEN1CHRNB2CHRNA4HTR2C
SCHEMBL12737660 0.86 SLC6A2 (0.49) QDPRSLC6A2SLC6A4SLC6A3KMT2A
Tert-Butyl Formate SCHEMBL27849353 0.84 MEN1 (0.45) QDPRSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL560750 0.83 HSP90AA1 (0.51) KMT2AMEN1MAPK1TSHRHSD17B10
SCHEMBL29729512 0.83 HSP90AA1 (0.51) KMT2AMEN1MAPK1TSHRHSD17B10
SCHEMBL23216721 0.81 QDPR (0.46) QDPRSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL4878435 0.81 NUDT1 (0.54) KMT2AMEN1MAPK1TSHRHSD17B10
SCHEMBL8313932 0.81 QDPR (0.55) QDPRCHRNB2CHRNA4HTR2C
Potassium SCHEMBL29827419 0.81 HSP90AA1 (0.54) KMT2AMEN1MAPK1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385938-B1 SULFONAMIDE DERIVATIVES PFIZER LTD (GB) 2015-03-04 EP disclosed
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
CN-102348697-A Sulfonamide derivatives PFIZER LTD 2012-02-08 CN disclosed
EP-2385938-A1 SULFONAMIDE DERIVATIVES Pfizer Limited (GB) 2011-11-16 EP disclosed
US-8040476-B2 Display device and method of producing the same MITSUBISHI ELECTRIC CORPORATION (JP) 2011-10-18 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 WO disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 QDPR 149/4885SLC6A2 252/4885SLC6A4 193/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 QDPR 149/4885SLC6A2 252/4885SLC6A4 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.